Tech Company Financing Transactions

Triplet Therapeutics Funding Round

Triplet Therapeutics secured a $59 million Series A financing round on 12/18/2019. Investors included MPM Capital, Pfizer Venture Investments and Alexandria Venture Investments.

Transaction Overview

Company Name
Triplet Therapeutics
Announced On
12/18/2019
Transaction Type
Venture Equity
Amount
$59,000,000
Round
Series A
Investors

MPM Capital (Lead Investor) (Shinichiro Fuse)

Pfizer Venture Investments (Lead Investor) (Laszlo Kiss)

Alexandria Venture Investments

Atlas Venture (Nessan Bermingham)

Invus

Partners Innovation Fund

Proceeds Purpose
The company will use the Series A funds to progress its first development candidates into IND-enabling studies, as well as to advance natural history studies to inform its clinical development plan and contribute to the scientific understanding of repeat expansion disorders.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. 1400W 14201
Cambridge, MA 02139
USA
Phone
(781) 299-7830
Website
www.triplettx.com
Email Address
[email protected]
Overview
Our mission is to prevent repeat expansion disorders and ensure a future for our patients. We are developing a fundamentally different treatment for repeat expansion disorders -- including Huntington's disease, myotonic dystrophy and spinocerebellar ataxias -- by addressing the underlying cause of the genetic dysfunction that drives disease onset and progression.
Profile
Triplet Therapeutics LinkedIn Company Profile
Social Media
Triplet Therapeutics Company Twitter Account
Company News
Triplet Therapeutics News
Facebook
Triplet Therapeutics on Facebook
YouTube
Triplet Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nessan Bermingham
  Nessan Bermingham LinkedIn Profile  Nessan Bermingham Twitter Account  Nessan Bermingham News  Nessan Bermingham on Facebook
Chief Financial Officer
Eric Sullivan
  Eric Sullivan LinkedIn Profile  Eric Sullivan Twitter Account  Eric Sullivan News  Eric Sullivan on Facebook
Vice President
Brian Bettencourt
  Brian Bettencourt LinkedIn Profile  Brian Bettencourt Twitter Account  Brian Bettencourt News  Brian Bettencourt on Facebook
Vice President
Salma Kiani
  Salma Kiani LinkedIn Profile  Salma Kiani Twitter Account  Salma Kiani News  Salma Kiani on Facebook
VP - Bus. Development
Irina Antonijevic
  Irina Antonijevic LinkedIn Profile  Irina Antonijevic Twitter Account  Irina Antonijevic News  Irina Antonijevic on Facebook
VP - Engineering
David Morrissey
  David Morrissey LinkedIn Profile  David Morrissey Twitter Account  David Morrissey News  David Morrissey on Facebook
VP - General Counsel
Jeffrey Cerio
  Jeffrey Cerio LinkedIn Profile  Jeffrey Cerio Twitter Account  Jeffrey Cerio News  Jeffrey Cerio on Facebook
VP - Human Resources
Amy Lurier
  Amy Lurier LinkedIn Profile  Amy Lurier Twitter Account  Amy Lurier News  Amy Lurier on Facebook
VP - Operations
John Cavanaugh
  John Cavanaugh LinkedIn Profile  John Cavanaugh Twitter Account  John Cavanaugh News  John Cavanaugh on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/18/2019: Voximplant venture capital transaction
Next: 12/18/2019: TMRW Life Sciences venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to document funding rounds that are announced publicly. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.